In a time of increasing cost pressures, limited resource capacity, and heightened demand for new treatments, Health Technology Assessments (HTAs) play a vital role in evaluating whether new
Value-based healthcare (VBHC) is gaining traction across the industry for its potential to improve patient care by standardising clinical and patient outcomes.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
